Posted by Michael Wonder on 04 Nov 2020
Salvia BioElectronics receives FDA breakthrough device designation for innovative neurostimulation solution
3 November 2020 - Salvia BioElectronics announced today that the U.S, FDA has granted breakthrough device designation for its implantable neurostimulation system to address chronic migraine.
Salvia is developing an innovative neurostimulation solution for chronic migraine based on a novel device concept with unique benefits to both patients and physicians.
